Andere Sprachen RespireRx Pharmaceuticals Inc.

Aktien

A2QQHJ

US7612273059

RSPI

Markt geschlossen - OTC Markets Andere Börsenplätze 21:55:31 03.05.2024			% 5 Tage	% 1. Jan.
0,0009 ^USD	-18,18 %		0,00 %	0,00 %

20.03.	RespireRx Pharmaceuticals Inc. meldet die Veröffentlichung von präklinischen Forschungsergebnissen, die die Fähigkeit von CX1739, seinem führenden klinischen AMPAkine, zur Verbesserung der Blasenfunktion nach Rückenmarksverletzungen belegen	CI
13.02.	RespireRx Pharmaceuticals Inc. meldet präklinische Schmerzlinderung für ihr nicht-opioides Hauptprodukt GABAkine	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	10.04.
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	20.03.
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	20.03.
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine	13.02.
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for Their Non-Opioid Lead GABAkine	13.02.
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors	22.01.
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dariusz Naziek to its Board of Directors	22.01.
RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	04.01.
Respirerx Pharmaceuticals Inc. Announces the Publication of A Case Report in Which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	04.01.
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development	11.12.
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17.11.
Today's Top OTC Stocks Watchlist (SWISF, EPAZ, ABQQ, RSPI)	13.10.23
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services	12.10.23
RespireRx Pharmaceuticals : SETTLEMENT AND EXCHANGE AGREEMENT - Form 8-K	02.10.23
Attention Deficit Hyperactivity Disorder Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	26.09.23
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21.08.23
CapitalGainsReport: Sub Penny Stocks Set To Soar: EPAZ, RSPI, TPTW, HGEN	10.08.23
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company	09.08.23
RespireRx Pharmaceuticals : Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Plan - Form 8-K	13.06.23
RESPIRERX PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	13.06.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen RespireRx Pharmaceuticals Inc.

Aktien

A2QQHJ

US7612273059

RSPI

Andere Sprachen

Filter